A disintegrin and metalloproteinase with thrombospondin motifs 13 · SINGLE PROTEIN · Homo sapiens
This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.
Move to another high-traffic target or paste a specific ChEMBL target ID.
Structured disease, protein, and project context should read before the lower-level identity rail.
As of 2026-09-12A disintegrin and metalloproteinase with thrombospondin motifs 13 shows approved-linked disease relevance led by acquired thrombotic thrombocytopenic purpura. 2 more disease programs remain visible in the same review block. 1 linked drug keeps the current disease frame grounded. Protein identity stays anchored to UniProt Q76LX8. Start with acquired thrombotic thrombocytopenic purpura, then reuse UniProt Q76LX8 as the stable protein anchor across project notes and exports.
Start with acquired thrombotic thrombocytopenic purpura, then reuse UniProt Q76LX8 as the stable protein anchor across project notes and exports.
A disintegrin and metalloproteinase with thrombospondin motifs 13 shows approved-linked disease relevance led by acquired thrombotic thrombocytopenic purpura. 2 more disease programs remain visible in the same review block. 1 linked drug remains visible in the same block.
Start review with acquired thrombotic thrombocytopenic purpura because it currently carries approved-linked support. Linked drugs include APADAMTASE ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
Disease source · ChEMBL drug mechanism + indication proxyA disintegrin and metalloproteinase with thrombospondin motifs 13
Review this target as A disintegrin and metalloproteinase with thrombospondin motifs 13, mapped to UniProt Q76LX8. Sequence length is 1427 aa.
Protein source · UniProt accession via ChEMBL component mappingKeep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.
This review treats A disintegrin and metalloproteinase with thrombospondin motifs 13 as ChEMBL target CHEMBL2346492, mapped to UniProt Q76LX8. Disease framing currently uses the Open Targets-ready proxy contract.
Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.
Choose the first block or source based on the question you are trying to answer.
Start here when your first question is whether A disintegrin and metalloproteinase with thrombospondin motifs 13 is the right protein anchor across sources, using UniProt Q76LX8 as the stable mapping.
Jump to Protein ContextUse this block first when you need to confirm why acquired thrombotic thrombocytopenic purpura is currently framed as approved-linked support. It currently carries 1 linked drug in the same disease frame.
Jump to Disease ContextOpen the one-page evidence card when you want the rationale, activity base, and attribution together.
Open Review-ready CardVerify identity, organism, and the fastest next research jumps from the same page.
| Preferred Name | A disintegrin and metalloproteinase with thrombospondin motifs 13 |
| Target Type | SINGLE PROTEIN |
| Organism | Homo sapiens |
| UniProt | Q76LX8 |
Reviewable protein naming and mapping context for this target snapshot.
| Protein Label | A disintegrin and metalloproteinase with thrombospondin motifs 13 |
| UniProt Accession | Q76LX8 |
| Component Type | Protein |
| Sequence Length | 1427 aa |
A disintegrin and metalloproteinase with thrombospondin motifs 13
Review this target as A disintegrin and metalloproteinase with thrombospondin motifs 13, mapped to UniProt Q76LX8. Sequence length is 1427 aa.
Open Targets-ready disease context using the current target-indication evidence contract.
A disintegrin and metalloproteinase with thrombospondin motifs 13 shows approved-linked disease relevance led by acquired thrombotic thrombocytopenic purpura. 2 more disease programs remain visible in the same review block.
Start review with acquired thrombotic thrombocytopenic purpura because it currently carries approved-linked support. Linked drugs include APADAMTASE ALFA. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.
| ChEMBL ID | pChEMBL | Type | Value (nM) | Phase |
|---|---|---|---|---|
| CHEMBL2347847 | 4.92 | IC50 | 12000.0 | Preclinical |
| CHEMBL2348091 | 4.7 | IC50 | 20000.0 | Preclinical |
| BAO Format | Assays | Compounds | Avg pChEMBL |
|---|---|---|---|
| single protein format | 3 | 2 | 4.8 |